Glyxambi
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 2406
  • Home
  • Print this page
  • Email this page

   Table of Contents      
LETTER TO THE EDITOR
Year : 2008  |  Volume : 56  |  Issue : 5  |  Page : 438-439

Combined photodynamic therapy and intravitreal ranibizumab as primary treatment for choroidal neovascularization associated with age-related macular degeneration in an Indian patient


Shri Bhagwan Mahavir Vitreretinal Services, Sankara Nethralaya, 18, College Road, Chennai - 600 006, Tamil Nadu, India

Date of Web Publication8-Aug-2008

Correspondence Address:
Pukhraj Rishi
Sankara Nethralaya, 18, College Road, Chennai - 600 006, Tamil Nadu
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0301-4738.42430

Rights and Permissions

How to cite this article:
Rishi P, Sen PR, Shroff D, Chhablani J. Combined photodynamic therapy and intravitreal ranibizumab as primary treatment for choroidal neovascularization associated with age-related macular degeneration in an Indian patient. Indian J Ophthalmol 2008;56:438-9

How to cite this URL:
Rishi P, Sen PR, Shroff D, Chhablani J. Combined photodynamic therapy and intravitreal ranibizumab as primary treatment for choroidal neovascularization associated with age-related macular degeneration in an Indian patient. Indian J Ophthalmol [serial online] 2008 [cited 2019 Dec 6];56:438-9. Available from: http://www.ijo.in/text.asp?2008/56/5/438/42430

Dear Editor,

We report the efficacy of combination therapy using photodynamic therapy (PDT) and intravitreal ranibizumab for choroidal neovascular membrane (CNVM) associated with age-related macular degeneration (ARMD) in an Indian patient, for the first time.

A 65-year-old lady presented with decreased vision in the left eye since four weeks. Right eye was phthisical with no perception of light. Vision was 20/80 in the left eye. Biomicroscopic evaluation of the anterior segment was unremarkable except for early cataractous changes. Fundus examination revealed an extrafoveal CNVM underlying the papillomacular bundle [Figure 1A]. Clinical findings were corroborated on fundus fluorescein angiography (FFA) [Figure 1B] and optical coherence tomography (OCT) [Figure 1C]. Considering the location of the CNVM and the single-eyed status of the patient, laser photocoagulation was thought to be best avoided. The patient underwent PDT as per standard protocol followed by intravitreal ranibizumab (0.5 mg), two days later. No treatment-related adverse effect was noted. At 16 weeks follow-up, visual acuity improved to 20/20. Clinical examination revealed regression of CNVM with no evidence of subretinal fluid. Clinical findings were confirmed on OCT which revealed a scarred CNVM with restoration of the retinal thickness and foveal contour [Figure 2]. The fundus remained stable and visual acuity was maintained at the sixth month follow-up.

Ranibizumab (Lucentis, Genetech, Inc, South San Francisco, California, USA) is an FDA-approved monoclonal antibody fragment that targets all vascular endothelial growth factor (VEGF)-A isoforms. [1] Combined treatment using PDT and bevacizumab has been shown to be effective in improving visual acuity and decreasing retreatment rates in choroidal neovascularization (CNV) associated with ARMD. [2] The combined regime is postulated to have a beneficial synergistic effect that could reduce the need for cyclic injections. [2],[3]

Combination therapy using ranibizumab and PDT has been reported previously in a single clinical trial in the Western literature, where the combination was found to be more efficacious than PDT alone. [4] VEGF inhibition alone could prevent neovascularization at an early developmental stage. However, once neovascular beds are established they are unlikely to regress with anti-VEGF therapy alone. [3] At this stage, a combined approach using a non-thermal laser has been seen to be beneficial. Since it is still unknown as to which stage CNV would become unresponsive to VEGF inhibition alone, combination therapy treatment using PDT and ranibizumab as the first-line management in such cases could be a viable option.

 
  References Top

1.
Rosenfeld PJ, Rich RM, Lalwani G. Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am 2006;19:361-72.  Back to cited text no. 1
    
2.
Spaide RF. Rationale for combination therapies for choroidal neovascularization. Am J Ophthalmol 2006;141:149-56.  Back to cited text no. 2
[PUBMED]  [FULLTEXT]  
3.
Dhalla MS, Shah GK, Blinder KJ, Ryan EH Jr, Mittra RA, Tewari A. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina 2006;26:988-93  Back to cited text no. 3
[PUBMED]  [FULLTEXT]  
4.
Heier JS, Boyer DS, Ciulla TA, Ferrone PJ, Jumper JM, Gentile RC, et al . Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: Year 1 results of the FOCUS Study. Arch Ophthalmol 2006;124:1532-42.  Back to cited text no. 4
[PUBMED]  [FULLTEXT]  


    Figures

  [Figure 1A], [Figure 1B], [Figure 1C], [Figure 2]


This article has been cited by
1 A New Vascular Pattern for Idiopathic Juxtafoveal Telangiectasia Revealed by the Retinal Function Imager
Gennady Landa, Richard B. Rosen
Ophthalmic Surgery Lasers and Imaging. 2010; 41(4): 413
[VIEW] | [DOI]



 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
References
Article Figures

 Article Access Statistics
    Viewed1564    
    Printed31    
    Emailed0    
    PDF Downloaded218    
    Comments [Add]    
    Cited by others 1    

Recommend this journal